Global Multiple Sclerosis Drugs Market Overview:
Multiple sclerosis (MS) is a neurological disease that affects the brain and spinal cord. The myelin sheath is affected by multiple sclerosis. The word "myelin sheath" refers to the material that covers and protects human nerve cells. Multiple sclerosis symptoms are caused by this damage, which blocks signals between the brain and the body. Depending on where the infected nerve fibres are located, signs and symptoms can vary widely from person to person and throughout the course of the disease. Symptoms of these can affect the movement like Numbness or weakness in one or more limbs that typically occurs on one side of your body at a time, or your legs and trunk, Certain neck movements, especially bending the neck forward, cause electric shock sensations. It can also cause vison problems like blurry vision or partial loss of vision. Other Symptoms include Slurred speech, Fatigue, Dizziness, Tingling or pain in parts of your body, Problems with sexual, bowel and bladder function. The majority of people with MS experience relapsing-remitting symptoms. They have relapses or cycles of new symptoms that last days or weeks and then recover partially or fully. Following these relapses, quiet periods of disease remission may last months or even years. The drugs used to treat this are called Multiple Sclerosis Drugs
- Growing instances of Multiple Sclerosis
- Increasing Awareness about health problems among people
- Increased Spending on Health
- Increased Investment in R&D
- Increasing Need For Better Multiple Sclerosis Treatment Options
- Side Effects of Multiple Sclerosis Medication
Some of the key players profiled in the report are Bristol Myers Squibb (United States), Genzyme Corporation (United States), Teva Pharmaceuticals (United States), Roche Holding AG (Switzerland), Merck KGaA (Germany), Mallinckrodt (Unite States), Pfizer Inc (United States), Hikma Pharmaceuticals PLC (United Kingdom), Par Pharmaceuticals (United States) and Cipla (India). Analyst at AMA Research see United States Players to retain maximum share of Global Multiple Sclerosis Drugs market by 2026. Considering Market by Route of Administration, the sub-segment i.e. Injectable will boost the Multiple Sclerosis Drugs market. Considering Market by Distribution Channel, the sub-segment i.e. Online will boost the Multiple Sclerosis Drugs market.
Latest Market Insights:
In August 2020, Genzyme Corporation signed acquisition agreement with Principia Biopharma Inc. a company engaged in the development of treatment solutions for immune mediated disease. This acquisition helped the company to enhance its research activities in the field of multiple sclerosis among other immune mediated disease.
January 2020 - Bristol Myers Squibb announced the launch of Zeposia, which is now the lowest priced oral MS drug available in the market.
The FDA is also requiring the makers of gadolinium contrast agents to conduct research to determine if there are harmful effects of gadolinium deposits. and The Consortium of MS Centers (CMSC) published an MRI Protocol and Clinical Guidelines for the Diagnosis and Follow-up of MS. These guidelines address the safety concerns with GBCAs and make recommendations for when using a contrast agent is necessary.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Multiple Sclerosis Drugs market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Multiple Sclerosis Drugs market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Manufacturers of Multiple Sclerosis Drugs, Suppliers of Multiple Sclerosis Drugs, Pharmaceutical Industry, Research Institutions, Regulatory Bodies and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.